Amneal Pharmaceuticals (AMRX) Capital Expenditures (2017 - 2026)

Amneal Pharmaceuticals has reported Capital Expenditures for 10 years, with the latest figure at $30.7 million in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 34.46% year-over-year to $30.7 million in Q2 2026; TTM through Jun 2026 was $72.9 million, a 7.12% increase from a year earlier, with the FY2025 full-year figure at $70.1 million, up 34.93% from the prior year.
• Capital Expenditures was $30.7 million for Q2 2026 at Amneal Pharmaceuticals, up from $8.2 million in the prior quarter.
• The five-year high for Capital Expenditures was $30.7 million in Q2 2026, with the low at $5.0 million in Q2 2022.
• Average Capital Expenditures over 5 years is $13.9 million, with a median of $11.8 million recorded in 2023.
• The largest YoY upside for Capital Expenditures was 137.73% in 2023 against a maximum downside of 38.95% in 2023.
• Over 5 years, Capital Expenditures stood at $11.5 million in 2022, then fell by 13.96% to $9.9 million in 2023, then surged by 53.62% to $15.2 million in 2024, then soared by 43.67% to $21.8 million in 2025, then jumped by 40.99% to $30.7 million in 2026.
• The last three Capital Expenditures figures came in at $30.7 million (Q2 2026), $8.2 million (Q1 2026), and $21.8 million (Q4 2025), per Business Quant data.